

Product Name	D&O and Excess D&O
Insurer	AXA-XL Insurance Company UK Limited
Responsible For	No
Manufacture	
Advised Sales	No
Product Type	Financial lines / Management Liability
Availability	Manually underwritten / prior submit to insurers
Target Market	UK based commercial customers with more than one year trading history. The
	product is suitable for private limited companies, charities, clubs and associations.
Non-Target	Non-Commercial customers.
Market	
(Unsuitable	
Markets)	
Why Is This	Specifically designed Directors & Officers policy wording affording the relevant
Product Suitable	covers required for these persons of an insured entity.
Are There Any	Yes – can include corporate legal liability and employment practices cover.
Optional Covers	
Distribution	SSR wholesale this product through other insurance intermediaries on behalf of
Methods	AXA-XL Insurance Company UK Limited. This product can be obtained by SSR on a
	manual referral basis or through the Angel underwriting system, but ultimate
. =1: 0 1 .	underwriting of the product is AXA-XL Insurance Company UK Limited.
Is This Product	Yes, this product is deemed to be providing fair value as it is specifically targeted in
Providing Fair	terms of coverage and function and is distributed via insurance intermediaries who
Value Risk To Fair Value	understand the requirements of their clients.  Duplication of covers elsewhere or failure to purchase required optional elements.
Mitigation	Excessive commission or fees may undermine the value of the product as well.
Wiitigation	Excessive commission of fees may undermine the value of the product as well.
	Care to be taken by distributors to ensure covers offered are not duplicating by
	other offerings. Commission levels charged by SSR and provided to distributors are
	within market norms and monitored for fairness regularly.
Other Information	Product documents can be provided upon request which clarifies position of
To Consider	product on standard exclusions and limitations to product coverage.
	Product manufacturer/insurer will produce their own Fair Value Statement and
	Target Market Statement.

Published	September 2023
Planned review	September 2024